SMT202000349T1 - Composizione farmaceutica secche comprendenti nanoparticelle di agente attivo legate a particelle di vettore - Google Patents

Composizione farmaceutica secche comprendenti nanoparticelle di agente attivo legate a particelle di vettore

Info

Publication number
SMT202000349T1
SMT202000349T1 SM20200349T SMT202000349T SMT202000349T1 SM T202000349 T1 SMT202000349 T1 SM T202000349T1 SM 20200349 T SM20200349 T SM 20200349T SM T202000349 T SMT202000349 T SM T202000349T SM T202000349 T1 SMT202000349 T1 SM T202000349T1
Authority
SM
San Marino
Prior art keywords
pharmaceutical compositions
active agent
carrier particles
dry pharmaceutical
nanoparticles bound
Prior art date
Application number
SM20200349T
Other languages
English (en)
Inventor
Maynard Emanuel Lichty
Garry T Gwozdz
Original Assignee
Besins Healthcare Lu Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl
Publication of SMT202000349T1 publication Critical patent/SMT202000349T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20200349T 2013-03-04 2014-03-03 Composizione farmaceutica secche comprendenti nanoparticelle di agente attivo legate a particelle di vettore SMT202000349T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772095P 2013-03-04 2013-03-04
EP14710757.7A EP2964199B1 (en) 2013-03-04 2014-03-03 Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
PCT/US2014/019833 WO2014137877A1 (en) 2013-03-04 2014-03-03 Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles

Publications (1)

Publication Number Publication Date
SMT202000349T1 true SMT202000349T1 (it) 2020-09-10

Family

ID=47901822

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200349T SMT202000349T1 (it) 2013-03-04 2014-03-03 Composizione farmaceutica secche comprendenti nanoparticelle di agente attivo legate a particelle di vettore

Country Status (23)

Country Link
US (2) US10695295B2 (it)
EP (1) EP2964199B1 (it)
JP (1) JP6564708B2 (it)
CN (1) CN105307639B (it)
AU (1) AU2014226192B2 (it)
BR (1) BR112015021525B1 (it)
CA (1) CA2901015A1 (it)
CY (1) CY1124635T1 (it)
DK (1) DK2964199T3 (it)
ES (1) ES2804702T3 (it)
HR (1) HRP20201103T1 (it)
HU (1) HUE050050T2 (it)
IL (1) IL240867B (it)
LT (1) LT2964199T (it)
MX (1) MX375187B (it)
PL (1) PL2964199T3 (it)
PT (1) PT2964199T (it)
RS (1) RS60481B1 (it)
RU (1) RU2715714C2 (it)
SI (1) SI2964199T1 (it)
SM (1) SMT202000349T1 (it)
WO (1) WO2014137877A1 (it)
ZA (1) ZA201505852B (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2715714C2 (ru) 2013-03-04 2020-03-03 Безен Хелткэа Люксембург Сарл Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя
WO2018025089A2 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Pharmaceutical compositions
WO2018213452A1 (en) * 2017-05-19 2018-11-22 Jackson Milton S Appetite suppressant
JP7453770B2 (ja) * 2019-10-25 2024-03-21 松本油脂製薬株式会社 複合粒子及びその製造方法
MX2023015529A (es) * 2021-06-25 2024-03-05 Nicoventures Trading Ltd Productos orales y metodo de fabricacion.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
FR2575678B1 (fr) 1985-01-04 1988-06-03 Saint Gobain Vitrage Ejecteur pneumatique de poudre
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
ATE247456T1 (de) * 1996-02-27 2003-09-15 Teijin Ltd Puderförmige zusammensetzung zur nasalen anwendung
WO2000012063A1 (en) 1998-08-26 2000-03-09 Teijin Limited Powdery pernasal compositions
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
ATE283048T1 (de) 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
RU2299743C2 (ru) 2001-07-05 2007-05-27 Транслэйшнл Рисерч Лтд. Композиции инсулина для носового введения
CN1176649C (zh) 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
JP2006516616A (ja) 2003-01-31 2006-07-06 オレクソ・アクチエボラゲット 即効薬剤組成物
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US7947308B2 (en) * 2005-07-20 2011-05-24 Raimar Loebenberg Effervescent powders for inhalation
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US20080057129A1 (en) * 2006-04-03 2008-03-06 Lerner E I Drug microparticles
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
CN101668544B (zh) * 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
GB0716907D0 (en) 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
WO2010033832A2 (en) * 2008-09-19 2010-03-25 Evestra, Inc. Estriol formulations
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
MX337126B (es) * 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
US20110262502A1 (en) 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
EP2560651A1 (en) * 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2627317A4 (en) * 2010-10-15 2014-08-20 Glaxo Group Ltd MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
EP2540281A1 (en) * 2011-06-30 2013-01-02 LEK Pharmaceuticals d.d. Solid self-microemulsifying systems
RU2715714C2 (ru) 2013-03-04 2020-03-03 Безен Хелткэа Люксембург Сарл Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя

Also Published As

Publication number Publication date
IL240867B (en) 2020-11-30
CY1124635T1 (el) 2022-03-24
RS60481B1 (sr) 2020-08-31
US10918601B2 (en) 2021-02-16
EP2964199A1 (en) 2016-01-13
US10695295B2 (en) 2020-06-30
RU2015141792A3 (it) 2018-03-01
HUE050050T2 (hu) 2020-11-30
AU2014226192B2 (en) 2018-07-26
JP6564708B2 (ja) 2019-08-21
US20200390706A1 (en) 2020-12-17
AU2014226192A8 (en) 2016-04-21
ES2804702T3 (es) 2021-02-09
SI2964199T1 (sl) 2020-10-30
CN105307639B (zh) 2020-06-30
RU2715714C2 (ru) 2020-03-03
RU2015141792A (ru) 2017-04-07
PT2964199T (pt) 2020-05-12
JP2016510742A (ja) 2016-04-11
PL2964199T3 (pl) 2021-01-25
BR112015021525B1 (pt) 2022-06-14
EP2964199B1 (en) 2020-04-22
WO2014137877A1 (en) 2014-09-12
IL240867A0 (en) 2015-10-29
ZA201505852B (en) 2017-07-26
CA2901015A1 (en) 2014-09-12
MX2015011624A (es) 2015-12-17
DK2964199T3 (da) 2020-06-15
AU2014226192A1 (en) 2015-09-03
BR112015021525A2 (pt) 2017-07-18
US20140248367A1 (en) 2014-09-04
LT2964199T (lt) 2020-08-10
CN105307639A (zh) 2016-02-03
HRP20201103T1 (hr) 2021-02-05
MX375187B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
GB2569249C (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents and uses thereof
EP3052551A4 (en) Benefit agent containing delivery particle
ZA201405694B (en) Virus like particle composition
GB201302427D0 (en) Nanoparticle delivery compositions
IL240148A0 (en) Biodegradable and clinically compatible nanoparticles as drug delivery carriers
EP2811980A4 (en) POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS AND METHODS OF USE THEREOF
GB201215289D0 (en) Nanoparticle formulation
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
PL2935375T3 (pl) Środek polimerowy do uzyskania stabilnej kompozycji wodnej zawierającej cząstki w zawiesinie
HUE051111T2 (hu) Foszfát kötõanyag részecskéket tartalmazó gyógyszerkészítmény
PL2836580T3 (pl) Mikrofibrylarna celuloza jako substancja czynna zdolna do odrywania brudu
SG11201507667SA (en) Fine dry particulate retinoid active agent compositions and topical formulations including the same
IL240867A0 (en) A dry preparation containing an active substance in the form of nanoparticles bound to carrier particles
IL236465B (en) Pharmaceutical composition for delayed release of active substances
ZA201505678B (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
IL235947A0 (en) History of isonicotinamide in solid state and pharmaceutical preparations containing them
PL3043791T3 (pl) Środek przeciwnowotworowy zawierający związek aminoacetonitrylowy jako substancję czynną
EP2814448A4 (en) GELIFYING AGENT FOR USE IN COSMETIC COMPOSITIONS
SG11201507651XA (en) Fine dry particulate resveratrol active agent compositions and topical formulations including the same
IL236367A0 (en) particle size reduction
TWI559972B (en) Microparticle and addition agent
ZA201507676B (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations